For example, plasma prekallikrein is a newly identified hepatokine that functions independently of PCSK9 to induce LDLR degradation, and genetic ablation or antibody neutralization of prekallikrein effectively reduces LDL-C levels as well as prevents atherosclerosis in multiple rodent models [153]. This evidence concerns the gene PCSK9 and atherosclerosis.